NUZ
NEURIZON THERAPEUTICS LIMITED
$0.0850
▼ -4.49%
Market cap
$67M
Turnover
$90,240
Last price
$0.0850
Day change
-4.49%
Announcements
15
Range, past year
Open 0.135 · Low 0.053 · Now 0.085 · High 0.185
Open NUZ in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NUZ momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
40/100
Wyckoff phase
Accumulation8d
Trend stage
Emerging
1 Day
-4.5%
1 Week
-2.3%
1 Month
+13.3%
1 Year
-39.3%
RSI
60
Avg daily range
5.5%
NEURIZON THERAPEUTICS LIMITED scores 40 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Fresh trend age (25 days)
- RSI in healthy zone (60)
Points to watch
- Thin liquidity
- Risk rating: High
- Composite downside risk elevated
NUZ announcements
Recent price-sensitive releases.
- 2026-10-06 FDA Type C Feedback, HEALEY trial potentially registrational Progress Report
- 2026-09-10 Neurizon Announces Partial Redemption of Convertible Notes Issued Capital - Other
- 2026-09-09 NIH funds Expanded Access Program for NUZ-001 in ALS Progress Report
- 2026-09-07 Neurizon Appoints Chief Executive Officer CEO/Managing Director - Appointment Resignation
- 2026-08-25 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-31 Appendix 4C & Quarterly Update Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-31 Neurizon Enters Strategic R&D Financing Facility Debt Facility
More Health Care stocks
Most traded in the same sector.